Table 3 Study drug-related treatment-emergent adverse events over 2 years
Event, n (%) | Eptinezumab 300 mg N = 128 |
|---|---|
Any study drug-related event | 18 (14.1) |
Hypersensitivity | 5 (3.9) |
Fatigue | 4 (3.1) |
Anaphylactic reaction | 1 (<1) |
Back pain | 1 (<1) |
Blood pressure systolic increased | 1 (<1) |
Constipation | 1 (<1) |
Dermatitis | 1 (<1) |
Dizziness | 1 (<1) |
Electrocardiogram ST segment depression | 1 (<1) |
Hypotension | 1 (<1) |
Influenza like illness | 1 (<1) |
Infusion site erythema | 1 (<1) |
Infusion site pruritus | 1 (<1) |
Lethargy | 1 (<1) |
Nausea | 1 (<1) |
Paresthesia | 1 (<1) |
Rhinitis | 1 (<1) |
Tremor | 1 (<1) |
Typical aura without headache | 1 (<1) |
Vision blurred | 1 (<1) |
Weight increased | 1 (<1) |